Want to see HK:1652 full AI Analyst Report?
1652 Stock Chart & Stats
HK$0.80
-HK$0.03(-4.41%)
At close: 4:00 PM EST
HK$0.80
-HK$0.03(-4.41%)
Day’s Range― - ―
52-Week RangeHK$0.63 - HK$1.44
Previous CloseN/A
Volume70.00K
Average Volume (3M)95.10K
Market Cap
HK$555.09M
Enterprise ValueHK$1.05K
Total Cash (Recent Filing)HK$87.82M
Total Debt (Recent Filing)HK$313.96M
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.15%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding739,301,000
10 Day Avg. Volume52,900
30 Day Avg. Volume95,100
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)1.48
Price to Sales (P/S)1.94
P/FCF Ratio7.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recent Cash GenerationPositive operating and free cash flow provide internal funding for operations and reduce reliance on external capital. Although recent cash generation is volatile, its presence offers useful support while management works to restore profitability.
Positive Equity BasePositive equity and a stable asset base provide a degree of balance-sheet resilience, helping the company absorb operating volatility. This foundation can preserve strategic flexibility if earnings recover, despite the constraints from increased leverage.
2025 Revenue ReboundThe strong 2025 revenue rebound indicates that demand or commercial execution can recover after a weak period. Sustained top-line improvement would improve operating leverage and create a platform for rebuilding margins, provided cost control also improves.
Bears Say
Sustained UnprofitabilityMulti-year losses show that revenue recovery has not yet translated into dependable earnings. Continued unprofitability can erode financial flexibility, limit reinvestment capacity, and make the business more dependent on cash reserves or additional financing.
Margin CompressionMargin compression weakens the economics of each unit sold and raises the execution burden required to reach profitability. Unless pricing, product mix, or production efficiency improves, higher revenue may continue to generate limited earnings and cash conversion.
Higher LeverageHigher leverage reduces financial flexibility while profitability remains weak. Debt servicing and refinancing needs could constrain investment or operating decisions, particularly if cash generation again becomes inconsistent or the earnings recovery takes longer.
Fusen Pharmaceutical Co., Ltd. News
1652 FAQ
What was Fusen Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Fusen Pharmaceutical Co., Ltd. lowest stock price was HK$0.63 and its highest was HK$1.44 in the past 12 months.
What is Fusen Pharmaceutical Co., Ltd.’s market cap?
Fusen Pharmaceutical Co., Ltd.’s market cap is HK$555.09M.
When is Fusen Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Fusen Pharmaceutical Co., Ltd.’s upcoming earnings report date is Mar 31, 2027 which is in 186 days.
How were Fusen Pharmaceutical Co., Ltd.’s earnings last quarter?
Fusen Pharmaceutical Co., Ltd. released its earnings results on Aug 31, 2026. The company reported -HK$0.021 earnings per share for the quarter.
Is Fusen Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Fusen Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Fusen Pharmaceutical Co., Ltd. pay dividends?
Fusen Pharmaceutical Co., Ltd. pays a Notavailable dividend of HK$0.004 which represents an annual dividend yield of 1.15%. See more information on Fusen Pharmaceutical Co., Ltd. dividends here
What is Fusen Pharmaceutical Co., Ltd.’s EPS estimate?
Fusen Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusen Pharmaceutical Co., Ltd. have?
Fusen Pharmaceutical Co., Ltd. has 739,301,000 shares outstanding.
What happened to Fusen Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Fusen Pharmaceutical Co., Ltd. reported an EPS of -HK$0.021 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Fusen Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1652
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fusen Pharmaceutical Co., Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Company Limited operates as an investment holding enterprise, primarily engaged in the manufacturing and distribution of a diverse range of pharmaceutical products across the People's Republic of China. Its extensive product portfolio includes specific cold remedies based on Shuanghuanglian, offered as both oral solutions and injections, alongside medications like flunarizine hydrochloride capsules and compound ferrous sulfate granules. The company further provides Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. Beyond these, Fusen actively researches, develops, produces, and markets a variety of proprietary Chinese medicines and modern Western pharmaceuticals, targeting conditions such as colds, fevers, cardiovascular ailments, and anemia. Additionally, the firm offers business management and advisory services. Fusen Pharmaceutical Company Limited was established in 2003 and is headquartered in Nanyang, China.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―